Blackstone Considered for PMG CRO and Pharma Divisions

Blackstone is reportedly testing the buyout market for Precision Medicine Group’s CRO and pharma commercialization divisions. The report frames the effort as a potential acquisition pathway focused on PMG’s services businesses rather than the entire company.

Precision Medicine Group was acquired in late 2020 by Berkshire Partners and TPG Growth for between $2.3bn and $2.4bn. The current discussion is described as sourced from industry participants, with no definitive agreement disclosed.